Online inquiry

IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5284MR)

This product GTTS-WQ5284MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets IL4-α gene. The antibody can be applied in Asthma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000589.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3565
UniProt ID P05112
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5284MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13999MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ9565MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ7990MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GX-H9
GTTS-WQ7096MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA FE 999301
GTTS-WQ10740MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA M-6495
GTTS-WQ11399MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-575
GTTS-WQ7472MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GBR-830
GTTS-WQ15137MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SYNT-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW